Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$674 Mln
P/E Ratio
--
P/B Ratio
3.34
Industry P/E
--
Debt to Equity
-9.17
ROE
-6.17 %
ROCE
-23.62 %
Div. Yield
0 %
Book Value
--
EPS
-0.37
CFO
$-528.57 Mln
EBITDA
$-513.88 Mln
Net Profit
$-596.20 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
| 27.14 | -26.58 | 24.93 | 144.89 | 22.76 | 17.92 | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
| 43.83 | 76.69 | -54.61 | -40.45 | -30.21 | -58.53 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable... glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Read more
Chairman & CEO
Mr. Paul R. Edick
Chairman & CEO
Mr. Paul R. Edick
Headquarters
Chicago, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Xeris Biopharma Holdings Inc (XERS) stood at $ 323 Mln as on 31-Dec-24
The share price of Xeris Biopharma Holdings Inc (XERS) is $4.31 (NASDAQ) as of 25-Apr-2025 16:24 EDT. Xeris Biopharma Holdings Inc (XERS) has given a return of 22.76% in the last 3 years.
Xeris Biopharma Holdings Inc (XERS) has a market capitalisation of $ 674 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Xeris Biopharma Holdings Inc (XERS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Xeris Biopharma Holdings Inc (XERS) and enter the required number of quantities and click on buy to purchase the shares of Xeris Biopharma Holdings Inc (XERS).
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
The CEO & director of Mr. Paul R. Edick. is Xeris Biopharma Holdings Inc (XERS), and CFO & Sr. VP is Mr. Paul R. Edick.
There is no promoter pledging in Xeris Biopharma Holdings Inc (XERS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Xeris Biopharma Holdings Inc. (XERS) | Ratios |
|---|---|
|
Return on equity(%)
|
301.32
|
|
Operating margin(%)
|
-13.11
|
|
Net Margin(%)
|
-27
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Xeris Biopharma Holdings Inc (XERS) was $0 Mln.
$0.03
(
